Anifrolumab

Drug Profile

Anifrolumab

Alternative Names: Anti-IFNaR MAb - Medarex/MedImmune; MDX-1333; MEDI-546

Latest Information Update: 23 Feb 2017

Price : $50

At a glance

  • Originator Medarex
  • Developer Medarex; MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action Interferon alpha beta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Systemic lupus erythematosus
  • No development reported Scleroderma

Most Recent Events

  • 11 Nov 2016 Immunogenicity data from the phase IIa trial in Systemic lupus erythematosus presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
  • 11 Nov 2016 Efficacy and pharmacokinetics data from phase II MUSE trial in Systemic lupus erythematosus presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2016)
  • 09 Nov 2016 AstraZeneca plans a phase II trial for Systemic lupus erythematosus (Adjunctive treatment) in USA, Hungary, Poland and South Korea (SC) (NCT02962960)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top